Compare EXR & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXR | TEVA |
|---|---|---|
| Founded | 1977 | 1901 |
| Country | United States | Israel |
| Employees | N/A | 32842 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9B | 36.7B |
| IPO Year | 2004 | N/A |
| Metric | EXR | TEVA |
|---|---|---|
| Price | $141.21 | $30.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 8 |
| Target Price | ★ $146.13 | $37.38 |
| AVG Volume (30 Days) | 1.1M | ★ 6.1M |
| Earning Date | 05-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.58% | N/A |
| EPS Growth | ★ 13.90 | N/A |
| EPS | ★ 4.59 | N/A |
| Revenue | ★ $3,377,542,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.47 | $2.51 |
| P/E Ratio | $30.83 | ★ $28.19 |
| Revenue Growth | ★ 3.70 | N/A |
| 52 Week Low | $121.03 | $12.47 |
| 52 Week High | $155.19 | $37.35 |
| Indicator | EXR | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 43.93 | 30.89 |
| Support Level | $135.61 | $15.93 |
| Resistance Level | $143.49 | $31.99 |
| Average True Range (ATR) | 3.69 | 0.98 |
| MACD | -0.95 | -0.43 |
| Stochastic Oscillator | 4.47 | 6.33 |
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 4,000 self-storage properties in 42 states, with over 300 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.